Navigation Links
New Cancer Treatment Shrinks Pancreatic Tumor
Date:11/23/2008

NASHVILLE, Tenn., Nov. 24 /PRNewswire/ -- A new cancer treatment is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a patient's large, stage 4 tumor was reduced in size by 70%. After seven more weeks of treatment, it no longer could be definitely identified on scans. Pancreatic cancer usually is fatal six to nine months after diagnosis. NeoPlas Innovation's combination of FDA-approved drugs appears to improve those odds for some patients, based on this result and similar ones seen before the protocol's public availability.

The tumor reduction correlated with resolution of the patient's symptoms of pain and digestive problems. "The cancer isn't gone," emphasized NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell. "There are still several metastatic lesions to address, but this kind of response is virtually unheard of in pancreatic cancer. At the very least, we're looking at his having many, many months of added survival with a quality of life he can truly enjoy."

The patient's daughter discussed her father's treatment, saying "He began the NeoPlas treatment after he became too ill to complete his final course of radiation following chemotherapy." She added, "Since then, he has been able to resume work two to three hours a day, go to lunch with other men and even take a ten-day trip to Europe with my brother."

The cholesterol drug Lovastatin is a key part of this treatment that has arrested or eradicated tumors in 78% of initial patients. The first person treated with the investigative protocol in 2000 had stage 4 melanoma; he remains disease-free today.

Based on experience and relevant lab research to date, staff members expect the best results for several malignancies. In addition to pancreatic cancer and melanoma, they include colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma.

Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.

A web site, http://www.neoplas.org, provides answers to common questions and a screening tool. Individuals can reach NeoPlas at 615-371-8100 or by e-mailing office@neoplas.org.

For an interview with Dr. Cantrell, call 615-371-8100 or e-mail office@neoplas.org.


'/>"/>
SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
2. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
3. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
4. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
5. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
6. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
7. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
8. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
9. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
10. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
11. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Maharashtra, February 12, 2016 ... Market research report titled Chronic Inflammation Global Clinical ... a snapshot of the global clinical trials landscape ... clinical trials by Region, Country (G7 & E7), ... point status and reviews top companies involved and ...
(Date:2/11/2016)... 2016 Laboratory glassware and plasticware ... These may range from microscope slides to large storage ... from borosilicate glass because of its low weight and ... hand, started gaining popularity over the past decade when ... glass with plastic in several applications due to its ...
(Date:2/11/2016)... 11, 2016 Potrero Medical, Inc., the developer of ... the appointment of George M. Rapier, III , MD, ... TX , WellMed is one of the nation,s largest ... HMO members in Texas and ... of his own internal medicine practice, he has been instrumental ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 12, 2016 , ... The Jones Agency, a family owned insurance company with ... a cooperative charity drive with the Tarrant Area Food Bank in the hopes of ... families in need, the Tarrant County Food Bank offers hope and security to the ...
(Date:2/12/2016)... ... 12, 2016 , ... Erlanger Agency has announced a new partnership in its ... campaign focuses on the fight against breast cancer, fundraising for a local woman named ... . , Carmen is a loving single mother of two boys who also serves ...
(Date:2/12/2016)... ... 12, 2016 , ... Donor Network West, the organ procurement organization that heals ... with San Ramon Regional Medical Center. Under the collaboration, the first of its kind, ... accommodate a more certain time frame for donor families for the recovery of organs. ...
(Date:2/12/2016)... , ... February 12, 2016 , ... For Coast Dental ... Suzan Sweeney, RDH, and dental assistant Terrell Moore shortly before 7 a.m. to volunteer ... of dental professionals, donating their time and skills to help hundreds of uninsured and ...
(Date:2/12/2016)... York, NY (PRWEB) , ... February 12, 2016 ... ... edition of “Revolutionizing Cancer Care.” , The print component of “Revolutionizing ... Chicago, Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of ...
Breaking Medicine News(10 mins):